Psychiatry is sued less often than most medical specialties, but the claims that do emerge are concentrating around routine parts of patient care - treatment management, medication monitoring and communication - in ways that create meaningful financial exposure for practices with inconsistent operational standards.
A September malpractice review from The Doctors Company examined 261 psychiatry claims from 2010 to 2025. Medical treatment was the most common major allegation, accounting for 43% of cases, while medication-related allegations made up 28%. An indemnity payment was made in 27% of the claims studied, with an average indemnity of $211,000 and average gross expenses of $76,000.
That severity sits against a comparatively low claim rate. The American Medical Association's 2026 analysis, based on combined 2022 and 2024 survey data, found that 0.5% of psychiatrists had been sued in the previous year and 9.2% had faced a claim at some point in their careers. Across all physicians, the corresponding figures were 1.8% and 29.7%.
The Doctors Company data also shows that the circumstances behind psychiatry claims vary considerably. Patient behavior was the most frequently identified contributing factor, appearing in 54.41% of cases, followed by clinical judgment at 41%, communication at 37.93% and documentation at 23.37%. Claims involving clinical judgment or communication carried average gross indemnity payments of $261,000, above the $211,000 average across all claims studied.
Patient non-adherence to treatment recommendations, medication regimens and follow-up appointments frequently contributed to adverse outcomes. Documentation deficiencies could also make it harder to demonstrate the reasoning behind treatment decisions, informed-consent discussions or continuity of care.
Separate claims data points to medication management as a particularly important source of financial exposure. A MedPro Group psychiatry analysis of 299 cases opened between 2014 and 2023 found medication-related allegations represented 33% of case volume but 47% of total dollars paid, including indemnity and expenses.
Within those medication cases, improper monitoring and management of a drug regimen appeared in 63%. Antidepressants were involved in 39% of medication-related cases and antipsychotics in 28%, with inadequate monitoring, medication selection and insufficient patient or family education among the recurring issues.
The two datasets cover different periods and claims populations and are not directly comparable. Taken together, however, they indicate that psychiatry's relatively favorable headline claim frequency can obscure meaningful differences in exposure between practices - particularly around medication monitoring, patient follow-up, clinical decision-making and documentation.
The Doctors Company review also highlighted exposures that extend outside the clinical relationship. One case involved a psychiatrist who did not report a patient's disclosure of past inappropriate sexual contact with a child after informally consulting colleagues. The subsequent claim identified reliance on informal peer advice, clinical judgment and insufficient documentation as contributing factors.
This category of claim is distinct from clinical negligence. Mandatory reporting obligations are statutory duties, and failures to comply sit outside the standard framework of treatment error - with implications for both coverage and licensure that go beyond the indemnity exposure a malpractice policy addresses. The review noted that documentation alone does not mitigate liability where mandatory reporting obligations have not been met.
The review recommended standardised suicide and violence risk assessments, clearer documentation of treatment decisions, stronger communication during transitions of care and formal escalation procedures for questions involving mandatory reporting.
"Every malpractice claim magnifies where patient care can be improved. Analyzing psychiatry claims highlights trends that provide clinicians with actionable insights to strengthen communication, decision-making, and overall patient care," said Julie Ritzman, senior vice president of patient safety and risk management at The Doctors Company.
That distinction comes as the medical professional liability market continues to face loss pressure. MPL specialist insurers recorded a collective $712 million underwriting loss in 2025, while direct premiums written rose 3.6% to $9.4 billion. Medical liability premiums also increased for a seventh consecutive year in 2025, with the AMA finding that almost 40% of premiums in its survey increased from the previous year.
For brokers placing MPL coverage for psychiatric practices, the claims data suggests the biggest differences in risk profile emerge not from the specialty itself, but from how consistently individual practices manage medications, monitor patients and document clinical decisions. In a low-frequency specialty, those operational differences can have an outsized effect when a claim does occur - and they are worth surfacing during coverage conversations before a practice's own loss history makes the point for them.
